Keay Nakae

Stock Analyst at Chardan Capital

(1.38)
# 1816
Out of 5,380 analysts
282
Total ratings
Success rate
Average return
40 Stocks
Name Action PT Current % Upside Ratings Updated
MNPR Monopar Therapeutics
Initiates Coverage On: Buy
60
33.11 81.21% 1 Jun 23, 2025
DYN Dyne Therapeutics
Maintains: Buy
50 50
10.62 370.81% 12 Jun 17, 2025
SLN Silence Therapeutics
Maintains: Buy
35 35
6.04 479.47% 12 Jun 13, 2025
RNA Avidity Biosciences
Maintains: Strong Buy
65 75
29.91 150.75% 17 Jun 9, 2025
SABS SAB Biotherapeutics
Maintains: Buy
20 20
1.77 1029.94% 15 May 15, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
20 20
3.22 521.12% 10 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
25 25
12.68 97.16% 2 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
14 14
5.79 141.8% 18 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
60 60
15.96 275.94% 19 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
2 6
8.38 -28.4% 10 May 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
5 5
0.73 584.93% 4 May 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
300 325
325 0% 13 May 2, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
20 20
1.15 1639.13% 14 Apr 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
6 6
1.78 237.08% 7 Mar 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
5 5
3.39 47.49% 12 Mar 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
3 3
2.41 3.73% 6 Mar 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
4 4
2.02 98.02% 14 Mar 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
10 8
0.89 798.88% 10 Nov 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
7 6
n/a n/a 6 Aug 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
7 5
n/a n/a 2 May 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 5 Feb 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
9
n/a n/a 6 Aug 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Sell
8 6
10.46 -42.64% 7 Aug 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
8
n/a n/a 5 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
50
n/a n/a 4 Nov 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
60 20
n/a n/a 4 Nov 10, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
65 55
6.74 716.02% 10 Nov 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
175 125
n/a n/a 4 Nov 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 5 Oct 17, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
2 10
5.84 71.23% 5 Aug 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Jun 27, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
3 2
n/a n/a 4 Apr 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
28 39
n/a n/a 4 Dec 9, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
100 88
14.46 505.12% 2 Sep 20, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
1 13
1.03 1162.14% 3 Feb 9, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Nov 3, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
155 40
3.2 1150% 2 Jun 30, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Terminates Coverage On: Buy
3 0
n/a n/a 3 May 5, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
65 70
n/a n/a 2 Mar 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
22500
n/a n/a 1 Jun 2, 2017